Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study.

By David M. Brown, P. Campochiaro, Rishi P. Singh, Zhengrong Li, Sarah Gray, Namrata Saroj, A. Rundle, Roman G. Rubio, W. Murahashi. Ophthalmology (Rochester, Minn.), 2010

1,107 citations recorded by the source corpus.

Subfields: Neurology, Ophthalmology

View Paper: https://www.semanticscholar.org/paper/1ee76b94def32b055c552004637d2d4540ccc29f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Neurology

1. N. Ferrara

In Ophthalmology

1. N. Ferrara
2. A. Adamis

Citations in the corpus

• Ten years of anti-vascular endothelial growth factor therapy (2016, positive): “As in AMD, the average patient in the DME and RVO trials gained vision with monthly ranibizumab therapy, which were early and sustained over time 216–226 .”